Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / The business of clinical research

Different kinds of studies: vaccines, devices, observational and decentralised trials

13 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Describe the particular features of vaccine trials, device trials and observational studies

  • Explain decentralised and hybrid trial elements and their data quality implications

  • Identify opportunities and challenges for research in African settings

Not all clinical research looks like a phase III drug trial. A professional needs to recognise how the principles apply across study types.

Vaccine trials

  • Participants are often healthy, so tolerance for risk is low and safety standards are very high.
  • Large sample sizes are needed for efficacy because disease incidence is low among those vaccinated and unvaccinated.
  • Immunogenicity (antibody or cell responses) is used as an endpoint, along with disease occurrence.
  • Follow-up includes solicited reactogenicity (diaries of expected local and general reactions in the days after vaccination) and long-term safety.
  • Community engagement is crucial, because trials often involve children and entire communities.

Medical device trials

  • Devices are regulated differently from drugs: classes by risk, performance and safety endpoints, and sometimes single-arm designs.
  • Operator training and learning curves influence results.
  • Blinding is often hard, and sham procedures raise ethical questions.
  • Standards such as ISO 14155 (Good Clinical Practice for devices) apply.

Observational and real-world studies

  • Cohort studies, registries, case-control studies and chart reviews.
  • Used for safety (pharmacovigilance), natural history, effectiveness in routine care, and health economics.
  • Ethics review is still required, though consent may sometimes be waived for anonymised records under strict conditions.
  • Data quality and bias control (confounding, selection) are central.
Vaccine trialDevice trialObservational studyHealthy volunteersLarge sample for efficacyReactogenicity diariesRisk-based classesOperator learning curveISO 14155No assigned interventionReal-world dataConfounding to manage
Study type shapes design, risk and operations.

Decentralised and hybrid trials

Decentralised clinical trials (DCTs) move some or all activities from research sites to participants' homes or local facilities, using tools such as telemedicine, home nursing, wearable devices, electronic consent, and direct-to-participant drug shipment. Hybrid trials combine site visits with decentralised elements.

Benefits: reduced travel, wider and more diverse participation, and better retention. Challenges: data security and privacy, identity verification, equipment and connectivity, supervision of remote procedures, product handling at home, and different rules between countries. Regulators allow these approaches when participant safety and data integrity are maintained.

Research in Africa

Opportunities: high burden of important diseases (malaria, HIV, TB, maternal and neonatal conditions, emerging infections), engaged communities, experienced research institutions and growing regulatory harmonisation.

Challenges: limited infrastructure and cold chain, sometimes lengthy approvals, shortage of trained staff, ethical issues of power and benefit-sharing, and the need for fair partnerships in which local researchers lead and benefit.

Worked example: hybrid design for a chronic disease trial

A 12-month hypertension trial in Uganda has 10 clinic visits in a conventional design. A hybrid design keeps 4 clinic visits (baseline, month 3, 6 and 12) and replaces 6 with home blood pressure readings reported by phone and village health team follow-up.

  • Participants save about 6 trips, perhaps 6 hours of travel each visit, a total of 36 hours and the transport cost.
  • Retention rises because visits are easier to keep.
  • Data quality requires validated automatic cuffs, training, and checks for missing readings. Remote readings are compared with clinic readings to confirm agreement.

Fewer visits do not remove the need for monitoring: it simply changes how and where the data are checked.

Fit the design to the question and the setting

Design, endpoints and operations should follow the research question, risks and the realities of participants' lives.

Convenience must not compromise safety or data

Remote procedures still need qualified oversight, clear escalation for safety problems, and validated tools.

Check yourself

Take a trial design you know. Which activities could safely move closer to participants, and what would you need to validate before doing so?

Summary

  • Vaccine, device and observational studies each have distinct risk profiles, endpoints and regulations.

  • Decentralised and hybrid trials reduce participant burden but need validation, privacy and oversight.

  • Research in Africa offers high-burden disease questions and strong communities, with infrastructure and equity challenges.

  • Design should follow the question and setting.

Check your understanding

Question 1
1

ISO 14155 concerns:

Question 2
2

Solicited reactogenicity in vaccine trials refers to:

Question 3
3

A decentralised trial moves some activities to:

Question 4
4

A challenge of observational studies is:

Question 5
5

A hybrid trial:

Question 6
6

Which is an important feature of vaccine trials in healthy volunteers?

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Pricing, contracts and managing the sponsor relationshipTrial and site close-out